Q-omics provides the consensus-scored RN7SKP285 profile across patient tissues and cancer cell-line models. RN7SKP285 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in TGCT. Among the 18 cancer types available for tumor–normal comparison, RN7SKP285 is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, RN7SKP285 RNA expression shows 10,841 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight TGCT, THCA, and THYM as cancer lineages where RN7SKP285 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SKP285 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SKP285 survival associations across molecular data types. RN7SKP285 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SKP285 RNA expression–survival associations across cancer types. High RN7SKP285 expression shows unfavorable associations in TGCT, KICH, LUSC, PCPG and PAAD, but favorable associations in BRCA. The TGCT Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify TGCT as the clearest survival context for RN7SKP285 RNA expression.
This table summarizes RN7SKP285 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SKP285. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SKP285 shows lower tumor expression in THCA, ESCA and LUSC and higher tumor expression in KICH, BLCA and STAD. The THCA box plot shows higher RN7SKP285 RNA expression in normal versus tumor tissue (log2 FC = −0.267, t-test p < 0.001).
This table shows molecular features associated with RN7SKP285 in patient tissues and cancer cell lines. In patient samples, RN7SKP285 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
